Eli Lilly (LLY) Gross Margin (2009 - 2026)

Eli Lilly (LLY) has reported Gross Margin for 18 consecutive years, with 81.93% the latest figure, recorded in Q1 2026.

• Gross Margin for Q1 2026 came in at 81.93%, down 59.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 82.83% (up 113.0% YoY), and the FY2025 annual result was 83.04%, up 173.0% from the prior year.
• Gross Margin was 81.93% for Q1 2026 at Eli Lilly, down from 82.52% in the prior quarter.
• Over five years, Gross Margin peaked at 84.27% in Q2 2025 and troughed at 73.47% in Q1 2022.
• Average Gross Margin over 5 years is 80.16%, with a median of 80.89% recorded in 2023.
• The widest YoY moves for Gross Margin: up 693 bps in 2022, down 162 bps in 2022.
• Over 5 years, Gross Margin stood at 78.8% in 2022, then increased by 3 bps to 80.89% in 2023, then grew by 2 bps to 82.24% in 2024, then grew by 0 bps to 82.52% in 2025, then declined by 1 bps to 81.93% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 81.93% in Q1 2026, 82.52% in Q4 2025, and 82.91% in Q3 2025.